The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -20,283 | -58,759 |
| Reduction in the carrying amount of rou assets, operating | 377 | 729 |
| Reduction in the carrying amount of rou assets, finance | 80 | 160 |
| Stock based compensation expense | 2,651 | 6,768 |
| Depreciation and amortization expense | 73 | 122 |
| Non-cash gain on long-term investment | 0 | 3,390 |
| Amortization of premium on investments in u.s. treasury securities | -60 | -46 |
| Prepaid expenses and other current assets | -2,140 | 2,566 |
| Accounts payable | -15,268 | 13,507 |
| Accrued expenses and other current liabilities | 996 | -4,822 |
| Lease liabilities, operating | -381 | -721 |
| Lease liabilities, finance | 8 | -9 |
| Net cash used in operating activities | -29,547 | -48,935 |
| Purchase of property and equipment | 289 | 108 |
| Purchases of investments | 0 | 55,366 |
| Proceeds from maturities of investments | 35,300 | 31,900 |
| Net cash provided by (used in) investing activities | 35,011 | -23,574 |
| Proceeds from exercise of stock options | 34 | - |
| Payments on finance leases | 83 | 281 |
| Proceeds from common stock issuances under 2023 espp | 101 | 170 |
| Proceeds from issuance of common stock, pre-funded warrants and warrants to purchase common stock upon may 2025 private placement offering | 0 | 79,999 |
| Third-party commissions and offering costs incurred upon private placement offering-May Two Thousand Twenty Five Private Placement | 0 | 6,917 |
| Net cash provided by financing activities | 52 | 72,971 |
| Net change in cash, cash equivalents and restricted cash | 5,516 | 462 |
| Cash and cash equivalents at beginning of period | 38,266 | - |
| Cash and cash equivalents at end of period | 44,244 | - |
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)